Dear Dr. Howell:

Please refer to your Supplemental New Drug Applications (sNDA) dated and received July 2, 2009 (NDA 19839/S-072 and NDA 20990/S-033), April 1, 2011 (NDA 19839/S-075 and NDA 20990/S-036), and April 21, 2011 (NDA 19839/S-076 and NDA 20990/S-037), submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Zoloft (sertraline hydrochloride) 25mg, 50mg, and 100mg Tablets (NDA 19839), and Zoloft (sertraline hydrochloride) 20mg/mL Oral Concentrate (NDA 20990).

We acknowledge receipt of your amendments dated:

Your October 27, 2010 submission constituted a complete response to our September 24, 2010 action letter for applications 19839/S-072 and 20990/S-033.

We also refer to your July 22, 2011, email correspondence agreeing to FDA’s May 3, 2011 proposed labeling which resulted in mutual labeling agreement for applications 19839/S-072 and 20990/S-033.

These supplemental new drug applications provide for the following revisions to the product labeling:

**19839/S-072 and 20990/S-033, submitted as “Prior Approval” supplements:**

These supplements provide for a comprehensive Medication Guide as requested in Agency correspondences dated April 16, 2009, and September 24, 2010.
19839/S-075 and 20990/S-036, submitted as “Changes Being Effected” supplements:

These supplements are in response to our March 4, 2011 supplement request letter to add a new subsection entitled Laboratory Tests under Precautions regarding the possibility of false-positive drug screens for benzodiazepines in patients taking sertraline.

19839/S-076 and 20990/S-037, submitted as “Changes Being Effected” supplements:

These supplements provide for the following changes to labeling:

1. Revisions to the Warnings section regarding coadministration of Zoloft with other serotonergic drugs.
2. Revisions to the Precautions section regarding diabetes and loss of glycemic control in patients taking selective serotonin reuptake inhibitors (SSRIs) including Zoloft.

We concur with your proposed changes to the Warnings section of labeling. However, we are further investigating the association between SSRIs and diabetes mellitus/loss of glycemic control. Therefore, we have administratively separated these changes to new labeling supplements (NDA 19839/S-079, NDA 20990/S-038). At this time, we will not take an action on 19839/S-079 and 20990/S-038 until a comprehensive review is conducted.

Additionally, we also refer to your Supplemental New Drug Applications, 19839/S-073 & 20990/S-034, submitted as “Changes Being Effected” labeling supplemental new drug applications which provided for revisions to Precautions-Nonteratogenic Effects section of the US Prescribing Information (USPI) concerning persistent pulmonary hypertension of the newborn (PPHN) associated with selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs) use. Although your proposed labeling has been incorporated into the attached labeling, we are still awaiting your response to the Agency’s complete response letter dated July 29, 2011, prior to making a final decision on these changes.

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at [http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm). Content of labeling must be identical to the enclosed labeling (text for the package insert, Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.
Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Shin-Ye Sandy Chang, Regulatory Project Manager, at (301) 796-3971.

Sincerely,

{See appended electronic signature page}

Thomas Laughren, M.D.
Director
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

THOMAS P LAUGHERN
08/19/2011